Sobi to list bond loan on NASDAQ OMX Stockholm and publishes prospectus

On 26 June 2012 Swedish Orphan Biovitrum AB (Sobi) issued a 5-year senior
unsecured bond loan in the total amount of SEK 600 million. Sobi has applied for
a listing of the bond loan on NASDAQ OMX Stockholm in accordance with the terms
and conditions of the bond loan and prepared a prospectus.
The prospectus has been approved by the Swedish Financial Supervisory Authority
and the bond loan is expected to be listed on NASDAQ OMX Stockholm on 16
November 2012. The prospectus is now available on Sobi's webpage & Media/Bond Loan.

For further information, please contact:
Åsa Stenqvist
Vice President, Head of Communications and Investor Relations (Interim)
Tel.: +46 8 697 21 88

Swedish Orphan Biovitrum (Sobi)
Sobi is an international healthcare company dedicated to bringing innovative
therapies and services to improve the lives of rare disease patients. The
product portfolio is primarily focused on inflammation and genetic diseases,
with three late stage biological development projects within hemophilia and
neonatology. Sobi also markets more than 40 products for companies in the
specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion
and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at

The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 12 November, 2012 at 12:45 p.m. CET.


Documents & Links